{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:51:03Z","timestamp":1763423463807,"version":"3.45.0"},"reference-count":72,"publisher":"Georg Thieme Verlag KG","issue":"10","funder":[{"name":"Huangshan City public health innovation development research\n                        project","award":["2023HYF-16"],"award-info":[{"award-number":["2023HYF-16"]}]},{"name":"Health research project of Anhui Province","award":["AHWJ2023BAc20027"],"award-info":[{"award-number":["AHWJ2023BAc20027"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Non-alcoholic fatty liver disease is the most common form of chronic liver\n                    disease. However, effective pharmacotherapy is still lacking. Sodium-glucose\n                    cotransporter-2 inhibitors have been proven to improve non-alcoholic fatty liver\n                    disease in previous clinical trials. In this work, an updated systematic review\n                    and meta-analysis of randomized controlled trials were performed to evaluate the\n                    efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients\n                    with non-alcoholic fatty liver disease. A literature search of PubMed, Cochrane,\n                    Web of Science, Medline, and Embase was performed up to August 2024. Articles\n                    were sieved to determine eligible randomized controlled trials. Review Manager\n                    version 5.4 software was used to conduct the meta-analysis. A total of 21\n                    randomized controlled trials with 1,311 participants were included. Compared\n                    with the controls, sodium-glucose cotransporter-2 inhibitor treatment\n                    significantly improved the controlled attenuation parameter, liver fat content,\n                    liver-to-spleen ratio, liver stiffness measurement, fibrosis-4 index, serum type\n                    IV collagen 7S level, serum alanine transaminase level, serum aspartate\n                    transaminase level, serum gamma-glutamyl transaminase level, fasting serum\n                    insulin level, homeostatic model assessment for insulin resistance, body weight,\n                    body mass index, visceral adipose tissue, and subcutaneous adipose tissue. The\n                    incidence of total adverse events was not significantly different between the\n                    sodium-glucose cotransporter-2 inhibition group and the control group.\n                    Sodium-glucose cotransporter-2 inhibitors can improve liver steatosis, liver\n                    fibrosis, liver enzymes, insulin resistance, and body composition in patients\n                    with non-alcoholic fatty liver disease. Sodium-glucose cotransporter-2\n                    inhibitors are safe and well tolerated. Sodium-glucose cotransporter-2\n                    inhibitors may become promising drugs for non-alcoholic fatty liver disease\n                    treatment.<\/jats:p>","DOI":"10.1055\/a-2720-5290","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:38:52Z","timestamp":1762213132000},"page":"593-604","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in\n                    Patients with Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review\n                    and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1055","volume":"57","author":[{"given":"Simei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huangshan City\n                    People's Hospital, Huangshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huangshan City\n                    People's Hospital, Huangshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huangshan City\n                    People's Hospital, Huangshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenliang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Huangshan City\n                    People's Hospital, Huangshan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Z M Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/MOL.0000000000000874","article-title":"Nonalcoholic fatty liver disease: an update","volume":"34","author":"G Bedogni","year":"2023","journal-title":"Curr Opin Lipidol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"15489","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"X Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"E E Powell","year":"2021","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1002916","DOI":"10.3389\/fendo.2022.1002916","article-title":"Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment","volume":"13","author":"W Che","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"G Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"L Rong","year":"2023","journal-title":"Front Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity","volume":"3","author":"H Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.5009\/gnl220545","article-title":"Nonalcoholic fatty liver disease as a systemic disease and the need for multidisciplinary care","volume":"17","author":"M Yoneda","year":"2023","journal-title":"Gut Liver"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"154001","DOI":"10.1016\/j.metabol.2019.154001","article-title":"Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!","volume":"101","author":"G Ranjbar","year":"2019","journal-title":"Metab Clin Exp"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"N Chalasani","year":"2017","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"M S Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e3292","DOI":"10.1002\/dmrr.3292","article-title":"Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes","volume":"36","author":"L Liu","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","article-title":"Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease","volume":"14","author":"Z C Dai","year":"2023","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"13381","DOI":"10.3390\/ijms241713381","article-title":"Advances in research on type 2 diabetes mellitus targets and therapeutic agents","volume":"24","author":"J Su","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"T Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"174272","DOI":"10.1016\/j.ejphar.2021.174272","article-title":"Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease","volume":"907","author":"E S Makri","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e0261310","DOI":"10.1371\/journal.pone.0261310","article-title":"Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model","volume":"17","author":"A Morishita","year":"2022","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.dld.2023.09.023","article-title":"Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors","volume":"56","author":"R Lombardi","year":"2022","journal-title":"Digestive Liver Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"M J Page","year":"2021","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e001990","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-Alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): A randomized prospective open-label controlled trial","volume":"9","author":"M Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref23","first-page":"102279","article-title":"Comparison between the effect of Empagliflozin and Pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"48","author":"L Hooshmand Gharabagh","year":"2024","journal-title":"ClRes Hepatol Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study","volume":"68","author":"H Tobita","year":"2021","journal-title":"J Clin Biochem Nutr"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of Ipragliflozin and Pioglitazone effects on Nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"D Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"T Kinoshita","year":"2020","journal-title":"J Diabetes Invest"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Y Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"ref28","first-page":"122","article-title":"Dapagliflozin therapy curative effect observation on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus","volume":"82","author":"C L Hu","year":"2020","journal-title":"Indian J Pharm Sci"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"M Shi","year":"2023","journal-title":"J Diabetes Complications"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT Trial)","volume":"41","author":"M S Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"H Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"J W Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"S Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol (Aust)"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"H Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"S Hiruma","year":"2023","journal-title":"Diabetes, Obes Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"M Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ph15121516","article-title":"The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients","volume":"15","author":"S H Elhini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: A 24-week randomized controlled trial","volume":"9","author":"E Han","year":"2020","journal-title":"J Clin Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"H Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"S A Harrison","year":"2022","journal-title":"Nat Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"T Shibuya","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s13410-021-00980-2","article-title":"Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients","volume":"42","author":"M Hussain","year":"2022","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1213\/ANE.0000000000001596","article-title":"Publication bias: the elephant in the review","volume":"123","author":"J E Dalton","year":"2016","journal-title":"Anesth Analg"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3390\/antiox11050975","article-title":"Modulation of oxidative stress-induced senescence during non-alcoholic fatty liver disease","volume":"11","author":"J Pedroza-Diaz","year":"2022","journal-title":"Antioxid (Basel)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"109199","DOI":"10.1016\/j.cbi.2020.109199","article-title":"High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms","volume":"330","author":"C Y Lian","year":"2020","journal-title":"Chem Biol Interact"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.31083\/j.fbl2807134","article-title":"SGLT-2 inhibitors for non-alcoholic fatty liver disease: a review","volume":"28","author":"R Xu","year":"2023","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"174304","DOI":"10.1016\/j.ejphar.2021.174304","article-title":"Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK\/mTOR pathway","volume":"907","author":"J Luo","year":"2021","journal-title":"Eur J Pharmacology"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.3350\/cmh.2022.0357","article-title":"Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future","volume":"29","author":"A Nogami","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41392-022-01119-3","article-title":"Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver\/steatohepatitis (NAFL\/NASH)","volume":"7","author":"X Xu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e29486","DOI":"10.1016\/j.heliyon.2024.e29486","article-title":"SGLT-2 inhibitors as novel treatments of multiple organ fibrosis","volume":"10","author":"J Hu","year":"2024","journal-title":"Heliyon"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1007\/s00210-023-02826-6","article-title":"Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-\u03baB\/SOX9\/OPN signaling and osteocalcin level","volume":"397","author":"M M Elseweidy","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.3748\/wjg.v26.i39.5919","article-title":"Clinical assessment and management of liver fibrosis in nonalcoholic fatty liver disease","volume":"26","author":"A Campos-Murgu\u00eda","year":"2020","journal-title":"World J Gastroenterol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/hep4.1637","article-title":"Type IV collagen 7S is the most accurate test for identifying advanced fibrosis in NAFLD with type 2 diabetes","volume":"5","author":"H Ishiba","year":"2021","journal-title":"Hepatol Commun"},{"key":"ref54","first-page":"817","article-title":"The past and present of serum aminotransferases and the future of liver injury biomarkers","volume":"15","author":"M R McGill","year":"2016","journal-title":"EXCLI J"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers","volume":"68","author":"N Vilar-Gomez EChalasani","year":"2018","journal-title":"J Hepatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12876-021-01790-w","article-title":"Normalization of gamma-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease","volume":"21","author":"Q Ma","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","article-title":"Efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial","volume":"12","author":"H Seino","year":"2021","journal-title":"Diabetes Ther"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"T Miyake","year":"2018","journal-title":"Open Med (Pol)"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"D M Tanase","year":"2020","journal-title":"J Diabetes Res"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4093\/dmj.2021.0280","article-title":"Insulin resistance: from mechanisms to therapeutic strategies","volume":"46","author":"S H Lee","year":"2022","journal-title":"Diabetes Metab J"},{"key":"ref61","first-page":"77","article-title":"Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clinical and Molecular","volume":"29","author":"K C Lee","year":"2023","journal-title":"Hepatology"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"R S Khan","year":"2019","journal-title":"Hepatology"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","article-title":"Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis","volume":"66","author":"B Radlinger","year":"2023","journal-title":"Diabetologia"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","article-title":"Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride\/glucose index","volume":"16","author":"D L Tahapary","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1507\/endocrj.EJ21-0725","article-title":"New classification and diagnostic criteria for insulin resistance syndrome","volume":"69","author":"W Ogawa","year":"2022","journal-title":"Endocr J"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cnur.2021.07.009","article-title":"Obesity and nonalcoholic fatty liver disease","volume":"56","author":"A Chaney","year":"2021","journal-title":"Nurs Clin North Am"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"F Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.clinre.2019.10.001","article-title":"Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?","volume":"44","author":"A Cordeiro","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"J W Pereira MJEriksson","year":"2019","journal-title":"Drugs"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"K Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e31508","DOI":"10.1097\/MD.0000000000031508","article-title":"Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs","volume":"101","author":"Y Zhao","year":"2022","journal-title":"Med (Baltim)"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11596-022-2573-9","article-title":"Efficacy of sitagliptin on nonalcoholic fatty liver disease in high-fat-diet-fed diabetic mice","volume":"42","author":"S T Zhou","year":"2022","journal-title":"Curr Med Sci"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"496453","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"T Ohki","year":"2012","journal-title":"ScientificWorldJournal"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2720-5290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:49:14Z","timestamp":1763423354000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2720-5290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":72,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,11,17]]},"published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2720-5290","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"type":"print","value":"0018-5043"},{"type":"electronic","value":"1439-4286"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}